Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
β Scribed by Fenaux, P; Chevret, S; Guerci, A; Fegueux, N; Dombret, H; Thomas, X; Sanz, M; Link, H; Maloisel, F; Gardin, C
- Book ID
- 110054634
- Publisher
- Nature Publishing Group
- Year
- 2000
- Tongue
- English
- Weight
- 163 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m^2^/day allβ__trans__βretinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AMLβBFM study group reduced the dosage to 25 mg/m^2^/day. For the lack of data on the use of A
Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients,